WallStreetZenWallStreetZen

NASDAQ: CCCC
C4 Therapeutics Inc Stock

$6.90+0.04 (+0.58%)
Updated Apr 23, 2024
CCCC Price
$6.90
Fair Value Price
-$1.16
Market Cap
$473.34M
52 Week Low
$1.06
52 Week High
$11.88
P/E
-2.58x
P/B
1.92x
P/S
13.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.76M
Earnings
-$132.49M
Gross Margin
100%
Operating Margin
-625.55%
Profit Margin
-638.3%
Debt to Equity
0.53
Operating Cash Flow
-$107M
Beta
1.95
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CCCC Overview

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies to degrade disease-causing proteins and thereby treat cancer, neurodegenerative conditions, and other diseases. The company uses its TORPEDO platform to synthesize targeted small molecule protein degraders, which employ a natural protein disposal system to catalyze the destruction of target proteins. C4 Therapeutics has strategic collaborations with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2015 and is headquartered in Watertown, MA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CCCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CCCC ($6.90) is overvalued by 694.21% relative to our estimate of its Fair Value price of -$1.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CCCC ($6.90) is not significantly undervalued (694.21%) relative to our estimate of its Fair Value price of -$1.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CCCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CCCC due diligence checks available for Premium users.

Be the first to know about important CCCC news, forecast changes, insider trades & much more!

CCCC News

Valuation

CCCC fair value

Fair Value of CCCC stock based on Discounted Cash Flow (DCF)
Price
$6.90
Fair Value
-$1.16
Undervalued by
694.21%
CCCC ($6.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CCCC ($6.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CCCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CCCC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.58x
Industry
16.46x
Market
41.92x

CCCC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.92x
Industry
5.93x
CCCC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CCCC's financial health

Profit margin

Revenue
$3.3M
Net Income
-$34.8M
Profit Margin
-1,065.7%
CCCC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CCCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$376.5M
Liabilities
$130.3M
Debt to equity
0.53
CCCC's short-term assets ($271.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CCCC's short-term assets ($271.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CCCC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CCCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$24.0M
Investing
$31.9M
Financing
$57.7M
CCCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CCCC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CCCC$473.34M+0.58%-2.58x1.92x
TSHA$473.16M+2.85%-2.64x6.31x
KALV$472.93M-2.01%-3.58x5.34x
APLT$472.26M+1.13%-3.14x-27.54x
HUMA$468.00M+6.22%-3.67x34.55x

C4 Therapeutics Stock FAQ

What is C4 Therapeutics's quote symbol?

(NASDAQ: CCCC) C4 Therapeutics trades on the NASDAQ under the ticker symbol CCCC. C4 Therapeutics stock quotes can also be displayed as NASDAQ: CCCC.

If you're new to stock investing, here's how to buy C4 Therapeutics stock.

What is the 52 week high and low for C4 Therapeutics (NASDAQ: CCCC)?

(NASDAQ: CCCC) C4 Therapeutics's 52-week high was $11.88, and its 52-week low was $1.06. It is currently -41.92% from its 52-week high and 550.94% from its 52-week low.

How much is C4 Therapeutics stock worth today?

(NASDAQ: CCCC) C4 Therapeutics currently has 68,600,669 outstanding shares. With C4 Therapeutics stock trading at $6.90 per share, the total value of C4 Therapeutics stock (market capitalization) is $473.34M.

C4 Therapeutics stock was originally listed at a price of $25.49 in Oct 2, 2020. If you had invested in C4 Therapeutics stock at $25.49, your return over the last 3 years would have been -72.93%, for an annualized return of -35.31% (not including any dividends or dividend reinvestments).

How much is C4 Therapeutics's stock price per share?

(NASDAQ: CCCC) C4 Therapeutics stock price per share is $6.90 today (as of Apr 23, 2024).

What is C4 Therapeutics's Market Cap?

(NASDAQ: CCCC) C4 Therapeutics's market cap is $473.34M, as of Apr 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

C4 Therapeutics's market cap is calculated by multiplying CCCC's current stock price of $6.90 by CCCC's total outstanding shares of 68,600,669.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.